ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2020
[Research Progress in the Pathogenesis of Idiopathic Pulmonary Fibrosis with Lung Cancer].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exogenous Thymosin Beta 4 Suppresses IPF-Lung Cancer in Mice: Possibly Associated with Its Inhibitory Effect on the JAK2/STAT3 Signaling Pathway.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by diffuse alveolitis and disorder of alveolar structure and eventually leads to pulmonary interstitial fibrosis. The cause of IPF is unknown and there is no effective treatment for IPF. There is no effective treatment for IPF, mainly to delay disease progression and improve patient's quality of life. At present, the incidence of IPF with lung cancer (IPF-LC) has increased significantly, which resulted in higher mortality and reduced quality of life. IPF-LC is more common in men, elderly, and smokers. It is a fatal disease and its clinical manifestations lack specificity. IPF-LC has no clear treatment plan, meanwhile, the median survival time is short, and the prognosis is poor. At present, the pathogenesis and treatment plan of IPF-LC are not clear. This article provides a brief review of the current research on the risk factors, pathogenesis, clinical characteristics and treatment of IPF-LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.